- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT02846220
Promoting Medication Adherence Among Older Adults With Hypertension
Overcoming Immunity to Change: A Feasibility Study of a New Method to Promote Medication Adherence Among Older Adults With Hypertension
Over 70% of US adults 65 or older are diagnosed with hypertension, the leading cause of cardiovascular disease and premature deaths in the world. Despite availability of effective drugs to control blood pressure, uncontrolled blood pressure and low adherence to antihypertensive drugs persist as major public health and clinical challenges. On average, 50% of adults adhere to chronic disease medications and lower levels of adherence are associated with worse blood pressure control and adverse outcomes. Many barriers to adherence are well known and have been targeted in interventions to improve medication adherence. As of yet, no single intervention has emerged as superior or even particularly effective in improving adherence. The investigators have recently identified unconscious, self-protective 'hidden motives' that contribute to nonadherence to chronic disease medications. There is a critical need to expand on this insight to test the potential for targeting individuals' 'hidden motives' for low adherence using an innovative learning process called Immunity-to-Change.
As a critical step in testing this intervention to target these 'hidden motives', the investigators will undertake a pilot study to assess the feasibility and acceptability of the Overcoming Immunity-to-Change intervention and determine effect sizes of the intervention on adherence, blood pressure (BP) control, and quality of life (QOL). The investigators will test the Immunity-to-Change intervention in a sample of nonadherent older adults with hypertension (n=18). Another sample of nonadherent older adults with hypertension will be monitored for comparison (n=18).
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Studientyp
Einschreibung (Tatsächlich)
Phase
- Unzutreffend
Kontakte und Standorte
Studienorte
-
-
Louisiana
-
New Orleans, Louisiana, Vereinigte Staaten, 70112
- Tulane University
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Men and women ages 55 and older, with the goal of a sex- and race-balanced sample
- Diagnosis of essential hypertension
- Uncontrolled hypertension
- Current treatment with antihypertensive medication
- Low antihypertensive pharmacy refill
- English speaking
- Telephone access
- Ability to read print on a computer screen and use the computer keyboard
- Written consent to participate and HIPAA authorization
- Written acceptance of study contract
- Approval of health care provider
Exclusion Criteria:
- Cognitive impairment
- Enrollment in another clinical trial
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
---|---|
Kein Eingriff: Übliche Pflege
|
|
Experimental: Health coaching
Two-hour in-person group counseling session led by health coach, involving development of personalized immunity maps that lay out adherence goal, behaviors that distract from goal, hidden motives that compete with achieving goal, and underlying assumptions Eight 50-minute individual telephone counseling sessions every three weeks with a health coach, focusing on uncovering hidden motives and challenging assumptions with the goal of overturning nonadherence mindsets |
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Change in medication adherence (PDC)
Zeitfenster: Baseline to 6 months
|
Change in proportion of days covered (PDC) from baseline to 6 months
|
Baseline to 6 months
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Change in medication adherence (MMAS-8)
Zeitfenster: Baseline to 6 months
|
Change in MMAS-8 score from baseline to 6 months
|
Baseline to 6 months
|
Change in medication adherence (KWood-4)
Zeitfenster: Baseline to 6 months
|
Change in KWood-4 score from baseline to 6 months
|
Baseline to 6 months
|
Change in medication adherence (MMAS-8)
Zeitfenster: Baseline to 3 months
|
Change in MMAS-8 score from baseline to 3 months
|
Baseline to 3 months
|
Change in medication adherence (KWood-4)
Zeitfenster: Baseline to 3 months
|
Change in KWood-4 score from baseline to 3 months
|
Baseline to 3 months
|
Change in proportion with low adherence (PDC)
Zeitfenster: Baseline to 6 months
|
Change in proportion with low adherence (PDC<0.8)
from baseline to 6 months
|
Baseline to 6 months
|
Change in proportion with low adherence (MMAS-8)
Zeitfenster: Baseline to 6 months
|
Change in proportion with low adherence (MMAS-8<6) from baseline to 6 months
|
Baseline to 6 months
|
Change in proportion with low adherence (KWood-4)
Zeitfenster: Baseline to 6 months
|
Change in proportion with low adherence (KWood-4>0) from baseline to 6 months
|
Baseline to 6 months
|
Change in proportion with low adherence (MMAS-8)
Zeitfenster: Baseline to 3 months
|
Change in proportion with low adherence (MMAS-8<6) from baseline to 3 months
|
Baseline to 3 months
|
Change in proportion with low adherence (KWood-4)
Zeitfenster: Baseline to 3 months
|
Change in proportion with low adherence (KWood-4>0) from baseline to 3 months
|
Baseline to 3 months
|
Change in systolic blood pressure
Zeitfenster: Baseline to 6 months
|
Change in systolic blood pressure from baseline to 6 months
|
Baseline to 6 months
|
Change in diastolic blood pressure
Zeitfenster: Baseline to 6 months
|
Change in diastolic blood pressure from baseline to 6 months
|
Baseline to 6 months
|
Change in systolic blood pressure
Zeitfenster: Baseline to 3 months
|
Change in systolic blood pressure from baseline to 3 months (if available from insurance records)
|
Baseline to 3 months
|
Change in diastolic blood pressure
Zeitfenster: Baseline to 3 months
|
Change in diastolic blood pressure from baseline to 3 months (if available from insurance records)
|
Baseline to 3 months
|
Change in proportion with controlled blood pressure
Zeitfenster: Baseline to 6 months
|
Change in proportion with controlled blood pressure (SBP<140 & DBP<90) from baseline to 6 months
|
Baseline to 6 months
|
Change in proportion with controlled blood pressure
Zeitfenster: Baseline to 3 months
|
Change in proportion with controlled blood pressure (SBP<140 & DBP<90) from baseline to 3 months
|
Baseline to 3 months
|
Change in health-related quality of life
Zeitfenster: Baseline to 6 months
|
Change in health-related quality of life score (SF-36) from baseline to 6 months
|
Baseline to 6 months
|
Change in health-related quality of life
Zeitfenster: Baseline to 3 months
|
Change in health-related quality of life score (SF-36) from baseline to 3 months
|
Baseline to 3 months
|
Andere Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Change in hidden motives score
Zeitfenster: Baseline to 6 months
|
Change in hidden motives score from baseline to 6 months
|
Baseline to 6 months
|
Change in hidden motives score
Zeitfenster: Baseline to 3 months
|
Change in hidden motives score from baseline to 3 months
|
Baseline to 3 months
|
Change in explicit attitudes score
Zeitfenster: Baseline to 6 months
|
Change in explicit attitudes score (Beliefs about Medicines Questionnaire) from baseline to 6 months
|
Baseline to 6 months
|
Change in explicit attitudes score
Zeitfenster: Baseline to 3 months
|
Change in explicit attitudes score (Beliefs about Medicines Questionnaire) from baseline to 3 months
|
Baseline to 3 months
|
Change in implicit attitudes score
Zeitfenster: Baseline to 6 months
|
Change in implicit attitudes score (d-score from single-category implicit association test) from baseline to 6 months
|
Baseline to 6 months
|
Change in explicit ambivalence score
Zeitfenster: Baseline to 6 months
|
Change in explicit ambivalence score (absolute value of difference between standardized positive and negative explicit attitudes scores) from baseline to 6 months
|
Baseline to 6 months
|
Change in explicit ambivalence score
Zeitfenster: Baseline to 3 months
|
Change in explicit ambivalence score (absolute value of difference between standardized positive and negative explicit attitudes scores) from baseline to 3 months
|
Baseline to 3 months
|
Change in implicit ambivalence score
Zeitfenster: Baseline to 6 months
|
Change in implicit ambivalence score (absolute value of difference between standardized explicit and implicit attitude scores)
|
Baseline to 6 months
|
Change in short risk aversion switch point
Zeitfenster: Baseline to 6 months
|
Change in short switch point on risk aversion scale from baseline to 6 months
|
Baseline to 6 months
|
Change in short risk aversion switch point
Zeitfenster: Baseline to 3 months
|
Change in short switch point on risk aversion scale from baseline to 3 months
|
Baseline to 3 months
|
Change in long risk aversion switch point
Zeitfenster: Baseline to 6 months
|
Change in long switch point on risk aversion scale from baseline to 6 months
|
Baseline to 6 months
|
Change in long risk aversion switch point
Zeitfenster: Baseline to 3 months
|
Change in long switch point on risk aversion scale from baseline to 3 months
|
Baseline to 3 months
|
Change in risk valuation
Zeitfenster: Baseline to 6 months
|
Change in value indicated on risk aversion scale from baseline to 6 months
|
Baseline to 6 months
|
Change in risk valuation
Zeitfenster: Baseline to 3 months
|
Change in value indicated on risk aversion scale from baseline to 3 months
|
Baseline to 3 months
|
Change in medication-taking self-efficacy (MUSE)
Zeitfenster: Baseline to 6 months
|
Change in score on MUSE medication-taking subscale from baseline to 6 months
|
Baseline to 6 months
|
Change in medication-taking self-efficacy (MUSE)
Zeitfenster: Baseline to 3 months
|
Change in score on MUSE medication-taking subscale from baseline to 3 months
|
Baseline to 3 months
|
Change in learning-about-medications self-efficacy (MUSE)
Zeitfenster: Baseline to 6 months
|
Change in score on MUSE learning-about-medications subscale from baseline to 6 months
|
Baseline to 6 months
|
Change in learning-about-medications self-efficacy (MUSE)
Zeitfenster: Baseline to 3 months
|
Change in score on MUSE learning-about-medications subscale from baseline to 3 months
|
Baseline to 3 months
|
Change in self-efficacy (MUSE)
Zeitfenster: Baseline to 6 months
|
Change in score on MUSE scale from baseline to 6 months
|
Baseline to 6 months
|
Change in self-efficacy (MUSE)
Zeitfenster: Baseline to 3 months
|
Change in score on MUSE scale from baseline to 3 months
|
Baseline to 3 months
|
Change in self-efficacy (Self-Efficacy for Managing Chronic Disease)
Zeitfenster: Baseline to 6 months
|
Change in score on SEMCD scale from baseline to 6 months
|
Baseline to 6 months
|
Change in self-efficacy (Self-Efficacy for Managing Chronic Disease)
Zeitfenster: Baseline to 3 months
|
Change in score on SEMCD scale from baseline to 3 months
|
Baseline to 3 months
|
Change in chronic stress
Zeitfenster: Baseline to 6 months
|
Change in chronic stress from baseline to 6 months, as measured by salivary cortisol
|
Baseline to 6 months
|
Change in perceived stress
Zeitfenster: Baseline to 6 months
|
Change in score on 4-item version of Perceived Stress Scale from baseline to 6 months
|
Baseline to 6 months
|
Change in perceived stress
Zeitfenster: Baseline to 3 months
|
Change in score on 4-item version of Perceived Stress Scale from baseline to 3 months
|
Baseline to 3 months
|
Mitarbeiter und Ermittler
Ermittler
- Hauptermittler: Marie A Krousel-Wood, MD MSPH, Tulane University
- Studienleiter: Erin M Peacock, PhD MPH, Tulane University
Publikationen und hilfreiche Links
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Tatsächlich)
Studienabschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Schätzen)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- 735133
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Hypertonie
-
Nantes University HospitalBeendetZirrhotischer Patient mit Verdacht auf portale Hypertension und im Rahmen eines OV-ScreeningsFrankreich